REYKJAVIK, Iceland, Feb. 6 /PRNewswire-FirstCall/ -- Scientists at deCODE genetics today present the discovery of two single letter variations in the sequence of the human genome (SNPs) conferring substantial increased risk of thyroid cancer. The two SNPs, located on chromosomes 9q22 and 14q13, are the first common variants replicated in multiple populations ever associated with increased risk of the disease. They were found through the analysis of the genomes of a total of more than 40,000 patients and control subjects from Iceland, the United States and Spain. Approximately 4 percent of people of European descent carry two copies of the at-risk versions of both SNPs, putting them at a 5.7-times greater risk of thyroid cancer than individuals who carry no copies of either. These variants contribute to an estimated 57 percent of all cases of the disease, and they associate with altered levels of key thyroid hormones.
“This is an important discovery with a clear medical utility. Thyroid cancer is the most common endocrine cancer, and about 1 percent of the general population will develop it at some point in their lifetime. But if detected early enough it is in general a treatable disease. Screening for the at-risk SNPs may therefore provide a new means of identifying those who are at highest risk, enabling closer monitoring of those individuals with an emphasis on addressing other risk factors and promoting early intervention if cancer is detected. We are already including these risk variants in our deCODEme full genome scan and deCODEme Cancer scan, and are analyzing the possibility of putting them into a reference laboratory diagnostic test,” said Kari Stefansson, CEO of deCODE and senior author on the study.
The paper, “Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations,” is published today in the online edition of Nature Genetics, at http://www.nature.com/ng.
deCODE would like to thank all those who participated in this study, as well as the collaborating clinicians and scientists from the National- University Hospital in Reykjavik, Ohio State University and the University of Zaragoza. This project was funded in part by the US National Institutes of Health under contracts CA16058 and CA124570.
About deCODE
deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company’s expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer’s disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE is offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer(TM), for the common forms of breast cancer. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com; on our diagnostics site at http://www.decodediagnostics.com; for our pioneering personal genome analysis service and new Cardio and Cancer scans, integrating the genetic variants included in these tests and those linked to another twenty common diseases, at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effects of the transfer of our common stock from the Nasdaq Global Market to the Nasdaq Capital Market and the potential delisting of our common stock from the Nasdaq Capital Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE’s filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Edward Farmer, +354-570-2819, edward.farmer@decode.is, or Gisli
Arnason, +354-570-1825, gisli.arnason@decode.is, or Joy Bessenger,
+1-212-481- 3891, joy.bessenger@decode.is
Web site: http://www.decode.com/
